Literature DB >> 23735753

Kinin-B2 receptor exerted neuroprotection after diisopropylfluorophosphate-induced neuronal damage.

W Torres-Rivera1, D Pérez, K-Y Park, M Carrasco, M O Platt, V A Eterović, P A Ferchmin, H Ulrich, A H Martins.   

Abstract

The kinin-B2 receptor (B2BKR) activated by its endogenous ligand bradykinin participates in various metabolic processes including the control of arterial pressure and inflammation. Recently, functions for this receptor in brain development and protection against glutamate-provoked excitotoxicity have been proposed. Here, we report neuroprotective properties for bradykinin against organophosphate poisoning using acute hippocampal slices as an in vitro model. Following slice perfusion for 10min with diisopropylfluorophosphate (DFP) to initiate the noxious stimulus, responses of pyramidal neurons upon an electric impulse were reduced to less than 30% of control amplitudes. Effects on synaptic-elicited population spikes were reverted when preparations had been exposed to bradykinin 30min after challenging with DFP. Accordingly, bradykinin-induced population spike recovery was abolished by HOE-140, a B2BKR antagonist. However, the kinin-B1 receptor (B1BKR) agonist Lys-des-Arg(9)-bradykinin, inducing the phosphorylation of mitogen-activated protein kinase (MEK/MAPK) and cell death, abolished bradykinin-mediated neuroprotection, an effect, which was reverted by the ERK inhibitor PD98059. In agreement with pivotal B1BKR functions in this process, antagonism of endogenous B1BKR activity alone was enough for restoring population spike activity. On the other hand pralidoxime, an oxime, reactivating acetylcholinesterase (AChE) after organophosphate poisoning, induced population spike recovery after DFP exposure in the presence of bradykinin and Lys-des-Arg(9)-bradykinin. Lys-des-Arg(9)-bradykinin did not revert protection exerted by pralidoxime, however when instead bradykinin and Ly-des-Arg(9)-bradykinin were superfused together, recovery of population spikes diminished. These findings again confirm the neuroprotective feature of bradykinin, which is, diminished by its endogenous metabolites, stimulating the B1BKR, providing a novel understanding of the physiological roles of these receptors.
Copyright © 2013 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-PAM; ACSF; AChE; B1BKR; B2BKR; BK; DFP; MEK/MAPK; N-methyl-d-aspartate; NMDA; OPs; PI3K; PS; acetylcholinesterase; artificial cerebrospinal fluid; bradykinin; diisopropylfluorophosphate; kinin-B1 receptor; kinin-B2 receptor; mitogen-activated protein kinase; neuroprotection; organophosphate; organophosphates; phosphatidylinositol kinase; population spike; pralidoxime

Mesh:

Substances:

Year:  2013        PMID: 23735753      PMCID: PMC3740336          DOI: 10.1016/j.neuroscience.2013.05.054

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  26 in total

Review 1.  Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment.

Authors:  Jirí Bajgar
Journal:  Adv Clin Chem       Date:  2004       Impact factor: 5.394

2.  Neuronal differentiation of P19 embryonal carcinoma cells modulates kinin B2 receptor gene expression and function.

Authors:  Antonio Henrique B Martins; Rodrigo R Resende; Paromita Majumder; Marcella Faria; Dulce E Casarini; Attila Tárnok; Walter Colli; João Bosco Pesquero; Henning Ulrich
Journal:  J Biol Chem       Date:  2005-03-14       Impact factor: 5.157

3.  Effects of K074 and pralidoxime on antioxidant and acetylcholinesterase response in malathion-poisoned mice.

Authors:  Alessandra Antunes dos Santos; Danúbia Bonfanti dos Santos; Renata Pietsch Ribeiro; Dirleise Colle; Kaite Cristiane Peres; Júlia Hermes; Anderson Machado Barbosa; Alcir Luiz Dafré; Andreza Fabro de Bem; Kamil Kuca; Marcelo Farina
Journal:  Neurotoxicology       Date:  2011-06-22       Impact factor: 4.294

4.  Electrical and Pharmacological Stimuli Reveal a Greater Susceptibility for CA3 Network Excitability in Hippocampal Slices from Aged vs. Adult Fischer 344 Rats.

Authors:  Daniel J Kanak; Ryan T Jones; Ashish Tokhi; Amy L Willingham; Hitten P Zaveri; Gregory M Rose; Peter R Patrylo
Journal:  Aging Dis       Date:  2011-08-30       Impact factor: 6.745

5.  Classification of kinin receptors.

Authors:  D Regoli; A Rizzi; S I Perron; F Gobeil
Journal:  Biol Chem       Date:  2001-01       Impact factor: 3.915

6.  Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation.

Authors:  Friederike Langhauser; Eva Göb; Peter Kraft; Christian Geis; Joachim Schmitt; Marc Brede; Kerstin Göbel; Xavier Helluy; Mirko Pham; Martin Bendszus; Peter Jakob; Guido Stoll; Sven G Meuth; Bernhard Nieswandt; Keith R McCrae; Christoph Kleinschnitz
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

Review 7.  A comprehensive review on experimental and clinical findings in intermediate syndrome caused by organophosphate poisoning.

Authors:  Mohammad Abdollahi; Somayyeh Karami-Mohajeri
Journal:  Toxicol Appl Pharmacol       Date:  2011-12-02       Impact factor: 4.219

8.  Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema.

Authors:  Madeleine Austinat; Stefan Braeuninger; João B Pesquero; Marc Brede; Michael Bader; Guido Stoll; Thomas Renné; Christoph Kleinschnitz
Journal:  Stroke       Date:  2008-11-06       Impact factor: 7.914

9.  Protection of DFP-induced oxidative damage and neurodegeneration by antioxidants and NMDA receptor antagonist.

Authors:  Snjezana Zaja-Milatovic; Ramesh C Gupta; Michael Aschner; Dejan Milatovic
Journal:  Toxicol Appl Pharmacol       Date:  2009-07-14       Impact factor: 4.219

10.  Bradykinin postconditioning protects pyramidal CA1 neurons against delayed neuronal death in rat hippocampus.

Authors:  Viera Danielisová; Miroslav Gottlieb; Miroslava Némethová; Petra Kravcuková; Iveta Domoráková; Eva Mechírová; Jozef Burda
Journal:  Cell Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.046

View more
  7 in total

Review 1.  Involvement of bradykinin in brain edema development after ischemic stroke.

Authors:  Marina Dobrivojević; Katarina Špiranec; Aleksandra Sinđić
Journal:  Pflugers Arch       Date:  2014-04-23       Impact factor: 3.657

2.  Mastoparan M extracted from Vespa magnifica alleviates neuronal death in global cerebral ischemia-reperfusion rat model.

Authors:  Mei Wang; Xiu-Mei Wu; Miao He; Heng Liu; Zhi-Bing Yang; Yue Li; Guang-Ming Wang; Hai-Rong Zhao; Cheng-Gui Zhang
Journal:  Iran J Basic Med Sci       Date:  2022-03       Impact factor: 2.532

3.  Kinin-B2 Receptor Activity in Skeletal Muscle Regeneration and Myoblast Differentiation.

Authors:  Janaina M Alves; Antonio H Martins; Claudiana Lameu; Talita Glaser; Nawal M Boukli; Vinicius Bassaneze; Rafael Dariolli; Isis C Nascimento; Poliana C M Martins; Héllio D N de Souza; José Eduardo Krieger; Dulce E Casarini; Vicencia M Sales; João B Pesquero; Henning Ulrich
Journal:  Stem Cell Rev Rep       Date:  2019-02       Impact factor: 5.739

4.  Kinin Peptides Enhance Inflammatory and Oxidative Responses Promoting Apoptosis in a Parkinson's Disease Cellular Model.

Authors:  Anna Niewiarowska-Sendo; Andrzej Kozik; Ibeth Guevara-Lora
Journal:  Mediators Inflamm       Date:  2016-09-18       Impact factor: 4.711

5.  Bradykinin-mediated Ca2+ signalling regulates cell growth and mobility in human cardiac c-Kit+ progenitor cells.

Authors:  Gang Li; Hui Che; Wei-Yin Wu; Ling-Jun Jie; Guo-Sheng Xiao; Yan Wang; Gui-Rong Li
Journal:  J Cell Mol Med       Date:  2018-08-17       Impact factor: 5.310

6.  Involvement of Bradykinin Receptor 2 in Nerve Growth Factor Neuroprotective Activity.

Authors:  Carla Petrella; Maria Teresa Ciotti; Robert Nisticò; Sonia Piccinin; Pietro Calissano; Simona Capsoni; Delio Mercanti; Sebastiano Cavallaro; Roberta Possenti; Cinzia Severini
Journal:  Cells       Date:  2020-12-10       Impact factor: 6.600

7.  The Bradykinin B2 Receptor Agonist (NG291) Causes Rapid Onset of Transient Blood-Brain Barrier Disruption Without Evidence of Early Brain Injury.

Authors:  Sergio R Rodríguez-Massó; Michelle A Erickson; William A Banks; Henning Ulrich; Antonio Henrique Martins
Journal:  Front Neurosci       Date:  2021-12-15       Impact factor: 4.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.